CD44 and colorectal carcinoma: Together, the results further provide evidence that mutant p53 could regulate chemoresistance of colorectal cancer through the TCF21/CD44 axis; expression changes of either TCF21 or CD44 could rescue the mutant p53-induced chemoresistance in colorectal carcinoma.